MIRA Pharmaceuticals Nears IND Submission, Strengthens Leadership and Drug Development Progress
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) is nearing the submission of its Investigational New Drug (IND) application for Ketamir-2 by the end of the year. The company has strengthened its leadership with the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Significant progress has been made with Ketamir-2, a novel oral ketamine analog, which has shown a superior safety profile and efficacy in preclinical studies. Additionally, MIRA-55, a novel oral pharmaceutical marijuana analog, has demonstrated promising results and is not classified as a controlled substance by the DEA.
August 19, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals is nearing the submission of its IND application for Ketamir-2, a novel oral ketamine analog, by the end of the year. The company has also appointed Dr. Itzchak Angel as Chief Scientific Advisor and reported promising preclinical results for Ketamir-2 and MIRA-55.
The nearing submission of the IND application for Ketamir-2 is a significant milestone that could lead to clinical trials and potential market approval, positively impacting MIRA's stock price. The appointment of Dr. Itzchak Angel adds credibility and expertise to the company's leadership. Promising preclinical results for both Ketamir-2 and MIRA-55 further enhance the company's prospects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100